Those are the findings of a new Georgetown University Medical Center study involving the review of almost 1,000 patient records from all seven acute care hospitals in Washington, DC. The new study will be published in the June 30th issue of American Stroke Association’s Stroke.
“Our study probably can be generalized to other urban communities in the US,” says Chelsea Kidwell, MD, director of the Georgetown University Stroke Center. “The good news is that the results of the study provide important information on how to improve stroke treatment care in African-Americans in the future,” she says.
The researchers looked at whether patients received the best drug possible to treat the most common type of stroke, called ischemic stroke. This type of stroke is caused by a blood clot that blocks blood flow in the brain. The drug tPA, or tissue plasminogen activator, is designed to break up the clot, which can reduce the effects of a stroke and reduce permanent disability. tPA is administered intravenously at a hospital and must be given within a few hours after the patient’s initial symptoms. Previous studies, however, have suggested that blacks are less likely than whites to receive tPA. Researchers set out to determine if the disparity existed in the District of Columbia and if so, what the reasons might be.
For the study, Kidwell and her colleagues reviewed 973 records from patients hospitalized with ischemic stroke at all seven Washington, DC acute care hospitals. Of the patients, 80 percent were black, and 20 percent were non-Hispanic white.
“In Washington, a predominantly black urban population, we found that blacks were a third less likely to be treated with tPA than whites,” explains Kidwell. She says understanding the reasons for this disparity are critical for making change in the future.
Researchers found that blacks were more likely to arrive at a hospital after the narrow treatment window during which tPA must be administered to be effective. Even if they arrived within three hours of symptom onset, blacks were still half as likely to be treated with tPA than whites.
“A key reason why fewer blacks received tPA appears to a greater rate of pre-existing medical conditions such as uncontrolled hypertension, recent stroke or being on blood thinners,” Kidwell explains. “These conditions make tPA administration unsafe.”
Uncontrolled hypertension accounted for nine percent of the patients who didn’t receive tPA. An additional 10 percent had a recent stroke or evidence of a prior hemorrhage.
After accounting for the differences, the researchers found that of the tPA eligible patients, the treatment rate for blacks and whites was actually similar.
“Our study not only demonstrates that there is a racial disparity in acute stroke treatment rates in this predominantly African-American urban population, but identifies two important underlying reasons: African-Americans do not get to the hospital early enough for treatment and they have a greater number of medical reasons for not receiving treatment,” says Kidwell.
“Interventions designed to increase treatment in this population need to focus on culturally relevant education programs designed to address barriers specific to this population,” she says.
This research was supported by grants to Kidwell at Georgetown University from the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Minority Health and Health Disparities (NIMHD), both part of the National Institutes for Health. Kidwell reports no personal financial interest related to the study.
About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC’s mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis — or “care of the whole person.” The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization (BGRO), which accounts for the majority of externally funded research at GUMC including a Clinical Translation and Science Award from the National Institutes of Health. In fiscal year 2009-2010, GUMC accounted for nearly 80 percent of Georgetown University’s extramural research funding.